GoodRx Holdings, Inc. Appoints New Chief Accounting Officer

GoodRx Holdings, Inc. (NASDAQ: GDRX) announced a significant leadership change that could have implications for shareholders and the company’s future financial strategy. On April 23, 2026, the Board of Directors appointed Thomas Chan as the Company’s new Chief Accounting Officer. Mr. Chan is also now designated as the principal accounting officer of the Company, with the appointment effective immediately.

Key Highlights of the Appointment

• Thomas Chan’s Background:
  • Age: 40
  • Joined GoodRx in October 2020
  • Held several key roles within the company, including:
    • Vice President, Corporate Controller (February 2024 – April 2026)
    • Vice President, Accounting & Reporting (May 2023 – February 2024)
    • Vice President, Financial Reporting & Quality (July 2022 – May 2023)
• Compensation and Incentives:
  • Annual base salary: \$350,000
  • Target annual bonus: 40% of base salary
  • Equity compensation:
    • Restricted Stock Unit (RSU) Award: Valued at \$131,250
    • Performance-Based Restricted Stock Unit (PSU) Award: Valued at \$43,750
    • Both awards are granted under the Company’s 2020 Incentive Award Plan.
    • RSUs vest in 12 equal quarterly installments (first vesting on August 15, 2026, contingent on continued employment).
    • PSUs vest in three equal installments, subject to achievement of performance goals and continued service.
    • The exact number of shares is determined by the average closing price of GoodRx stock over the 30 days prior to the grant date.

Key Information for Shareholders

• Price Sensitivity:
  • This leadership change brings a seasoned internal finance executive into a key oversight position. Given Mr. Chan’s extensive knowledge of the Company’s financial systems and processes, his appointment may be viewed positively by markets seeking continuity and expertise in financial reporting and compliance.
  • The structure of the equity awards, especially the performance-based portion, aligns Mr. Chan’s interests with those of shareholders and could incentivize strong financial performance.
  • No related party transactions or family relationships were disclosed in connection with this appointment.
  • Mr. Chan has entered into GoodRx’s standard indemnification agreement for directors and officers.
• Other Relevant Company Details:
  • Trading Symbol: GDRX
  • Exchange: NASDAQ
  • Class of Securities Registered: Class A Common Stock, \$0.0001 par value per share
  • Company Headquarters: 2701 Olympic Boulevard, Santa Monica, CA 90404
  • Business Phone: (855) 268-2822

Potential Impact on Share Price

• The appointment of a new Chief Accounting Officer is a material change for GoodRx, as the role is central to financial reporting, compliance, and internal controls—areas that are closely watched by both investors and regulators.
• The fact that the new appointee has been promoted from within suggests stability and a deep understanding of the Company’s financial operations, which could be reassuring to investors and potentially supportive of the share price.
• The performance-based equity grants indicate a focus on driving future shareholder value, aligning executive compensation with Company performance.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult with a qualified advisor before making investment decisions. The information above is based on the company’s public SEC filing and may be subject to change.

View GoodRx Holdings, Inc. Historical chart here